Fundz

Plateletbio Completes $75.5M Series B Financing

PRIVATENov 04, 2021

Amount Raised

$75.5 Million

Round Type

Series B

CambridgeOtherBiotechnology

Description

PlateletBio, a preclinical-stage biotechnology company pioneering an entirely new platform of allogeneic cell therapies based on platelet biology, today announced that it has raised $75.5 million in Series B financing. The round includes new investors SymBiosis, K2 HealthVentures and Oxford Finance as well as participation from existing investors Ziff Capital Partners and Qiming Venture Partners.

Who else raised in Biotechnology around the same time

Companies in the same sectors as Platelet BioGenesis, Inc. that raised within 45 days of this round, from Fundz verified event records.

  • AMBERSTONE BIOSCIENCES, INC. raised $6M on December 17, 2021.
  • SunBird Bio raised $18M on December 17, 2021.
  • Plastomics raised $7.1M on December 17, 2021.
  • Cardio Diagnostics Inc. raised $1.1M (Seed) on December 17, 2021.
  • 20n Bio raised $3.3M (Seed) on December 17, 2021.
  • Cresilon raised $25M on December 17, 2021.

Who to call at Platelet BioGenesis, Inc., and when

A new round usually means Platelet BioGenesis, Inc. is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Platelet BioGenesis, Inc. raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Platelet BioGenesis, Inc., from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Platelet BioGenesis, Inc.. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Platelet BioGenesis, Inc.

Location

325 VASSAR ST., SUITE 2A

Cambridge, Maryland, United States

About

Inspired by the biological function and versatility of platelets, PlateletBio is pioneering the next generation of safer, more effective cell therapies. Its cell therapy platform produces “platelet-like cells” (PLCs) capable of performing vital biological functions and able to be genetically engineered into multiple allogeneic cell therapies. The company, based in Watertown, Massachusetts, is focused on advancing a diverse pipeline of next-generation cellular therapies for applications in autoimmune diseases, hematology, and inflammation. Visit www.plateletbio.com for more information.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Platelet BioGenesis, Inc. raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Predictive Intelligence
Strategic

ML-powered predictions for Platelet BioGenesis, Inc.'s next move

See what Strategic adds

Funding Insights

What this usually means
Timeline to next round
Series B companies typically work for 15-20 months before raising new capital
Growth expectations
Series B companies are expected to scale rapidly and expand market reach

Platelet BioGenesis, Inc. raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.